Drug Trial Radar · NCT01964989
Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.
Last checked: Nov 20, 2026Latest source record: Mar 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10,644
Actual
Start
Nov 2013
Primary completion
Oct 2015
Study completion Aug 2016
Sponsor
- Lead sponsor
- SeqirusIndustry
- Sponsor type
- Industry
- Collaborators
- Novartis Vaccines
- First posted
- Oct 17, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 6 months, up to 71 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to \<72 Months of Age. The study was conducted during the 2013/2014 and 2014/2015 northern hemisphere influenza season.
Conditions
- Influenza Virus
Interventions
Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)Biological
1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)Biological
1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy Endpoint: First-Occurrence Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Confirmed Influenza A and/or B of Any Influenza Strain in Subjects ≥6 to <72 Months of AgeTime frame: ≥21 days and ≤180 days after the last vaccination or until the end of the influenza season (Northern Hemisphere: end of June; Southern Hemisphere: end of December; Philippines/Thailand: end of October), whichever was longer
Locations
167 sites in 11 countries. Site status is shown where the registry gives one.
222, Novartis Investigational Site
Chandler, Arizona
267, Novartis Investigational Site
Harrisburg, Arkansas
259, Novartis Investigational Site
Anaheim, California
280, Novartis Investigational Site
Anaheim, California
213, Novartis Investigational Site
Baldwin Park, California
407, Novartis Investigational Site
Downey, California
238, Novartis Investigational Site
La Puente, California
411, Novartis Investigational Site
Ontario, California
202, Novartis Investigational Site
Paramount, California
250, Novartis Investigational Site
San Diego, California
293, Novartis Investigational Site
San Francisco, California
243, Novartis Investigational Site
Colorado Springs, Colorado
249, Novartis Investigational Site
Denver, Colorado
229, Novartis Investigational Site
Boca Raton, Florida
416, Novartis Investigational Site
Hialeah, Florida
287, Novartis Investigational Site
Hialeah, Florida
412, Novartis Investigational Site
Homestead, Florida
224, Novartis Investigational Site
Melbourne, Florida
417, Novartis Investigational Site
Miami, Florida
404, Novartis Investigational Site
Miami, Florida
285, Novartis Investigational Site
Miami, Florida
277,Novartis Investigational Site
Miami, Florida
234, Novartis Investigational Site
Opa-locka, Florida
297, Novartis Investigational Site
Orlando, Florida
297, Novartis Investigational vaccine
Orlando, Florida
410, Novartis Investigational Site
Sarasota, Florida
401, Novartis iNvestiagtional Site
Atlanta, Georgia
299, Novartis Investigational Site
DeKalb, Illinois
268, Novartis Investigational Site
Peoria, Illinois
209, Novartis Investigational Site
Augusta, Kansas
210, Novartis Investigational Site
Newton, Kansas
274 Novartis Investigational Site
Park City, Kansas
211, Novartis Investigational Site
Wichita, Kansas
269, Novartis Investigational Site
Bardstown, Kentucky
226, Novartis Investigational Site
Louisville, Kentucky
248, Novartis Investigational Site
Louisville, Kentucky
207, Novartis Investigational Site
Louisville, Kentucky
290, Novartis Investigational Site
Louisville, Kentucky
265, Novartis Investigational Site
Haughton, Louisiana
408, Novartis Investigational Site
Mangham, Louisiana
Showing 40 of 167 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.